Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy

Award Number: R01CA256969
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2021
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy - PROJECT SUMMARY: Pancreatic ductal adenocarcinoma (PDA) will become the 2nd leading cause of cancer deaths in the United States by 2030. Most patients with PDA present with nonresectable/metastatic disease, and systemic chemotherapy is the anchoring treatment in these patients. Surgery is an option in the minority of patients (~30%) who present with localized disease, though most develop early recurrence after a highly morbid surgery due to occult metastases. Therefore, neoadjuvant therapy (NAT) is an emerging standard approach, but is only beneficial if the selected systemic therapy is effective. Indeed, for all patients with PDA, metastatic or otherwise, the duration of effective systemic therapy is the most important factor in their survival. There is a critical unmet need for accurate and timely assessment of treatment response in order to 1) get patients on effective systemic therapy as soon as possible and keep them on it as long as possible, 2) expeditiously discontinue toxic, costly and ineffective therapies, and 3) facilitate evidence-based personalized clinical decisions regarding curative- intent surgery. Current management of PDA relies principally on computed tomography (CT) and tumor markers (CA19-9). However, these tools are not sensitive enough and are too slow for adjudicating benefit in patients with rapidly lethal metastatic disease, and for identifying suitable candidates most likely to benefit from surgery after NAT. We now have cutting-edge tools for more precise quantification of disease burden at the molecular and metabolic levels. We have previously shown that mutant KRAS circulating tumor (ct)DNA can be detected with high sensitivity in PDA, tends to drop rapidly with effective therapy, and may be a more dynamic predictor of therapy response than CA19-9. We have also shown that metabolic imaging with hybrid integrated 18-fluoro- deoxyglucose (FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) improves the detection of subtle metastases that are occult on CT, early response assessment in patients with nonresectable/metastatic PDA, and prediction of pathological response to NAT in patients who undergo resection. Building on these promising results, we hypothesize that the appropriate combination of KRAS ctDNA and PET/MRI biomarkers will enable timely assessment of the clinical utility of therapy in PDA patients. In Aim 1, we will define thresholds for early chemotherapy switch in unresectable/metastatic PDA using dynamic and quantitative changes in KRAS ctDNA and FDG PET/MRI biomarkers for use in future prospective trials. In Aim 2, we will construct, test and validate a model of surgical benefit or futility for patients with potentially resectable PDA using dynamic KRAS ctDNA and FDG PET/MRI response data. Our overarching goal is to integrate reliable biomarkers that can accurately guide therapy and enable precision medicine to improve outcomes of patients with this deadly disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $544,053 )
2026	2026	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	6	3/23/2026	NON-COMPETING CONTINUATION	$544,053
														Subtotal = $544,053

Issue Date FY: 2025 ( Subtotal = $1 )
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	003	5	5/16/2025	NON-COMPETING CONTINUATION	$1
2025	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	4	11/29/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2025	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	002	4	3/3/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2025	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Detection and Diagnosis Research	001	3	2/19/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $1

Issue Date FY: 2024 ( Subtotal = $702,342 )
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	001	4	9/16/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$702,342
2024	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Detection and Diagnosis Research	000	3	9/16/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $702,342

Issue Date FY: 2023 ( Subtotal = $598,284 )
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Detection and Diagnosis Research	000	3	2/27/2023	NON-COMPETING CONTINUATION	$598,284
														Subtotal = $598,284

Issue Date FY: 2022 ( Subtotal = $596,548 )
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Detection and Diagnosis Research	001	2	4/28/2022	NON-COMPETING CONTINUATION	$48,700
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Detection and Diagnosis Research	000	2	3/4/2022	NON-COMPETING CONTINUATION	$547,848
														Subtotal = $596,548

Issue Date FY: 2021 ( Subtotal = $624,558 )
2021	2021	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Detection and Diagnosis Research	000	1	3/22/2021	NEW	$624,558
														Subtotal = $624,558

Grand Total All Awards = $3,065,786

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy

Award Number: R01CA256969

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2021

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer